Author:
Yashiro M,Qiu H,Hasegawa T,Zhang X,Matsuzaki T,Hirakawa K
Publisher
Springer Science and Business Media LLC
Reference40 articles.
1. Arnold D, Peinert S, Voigt W, Schmoll HJ (2006) Epidermal growth factor receptor tyrosine kinase inhibitors: present and future role in gastrointestinal cancer treatment: a review. Oncologist 11: 602–611
2. Becker JC, Muller-Tidow C, Serve H, Domschke W, Pohle T (2006a) Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12: 3297–3305
3. Becker JC, Muller-Tidow C, Stolte M, Fujimori T, Tidow N, Ilea AM, Brandts C, Tickenbrock L, Serve H, Berdel WE, Domschke W, Pohle T (2006b) Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer. Int J Oncol 29: 615–623
4. Bugat R (2003) Irinotecan in the treatment of gastric cancer. Ann Oncol 14 (Suppl 2): ii37–ii40
5. Chang GC, Yu CT, Tsai CH, Tsai JR, Chen JC, Wu CC, Wu WJ, Hsu SL (2008) An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. Eur J Pharmacol 600: 37–44
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献